Europe Anticoagulant Reversal Drug Market is expected to reach US$ 655.4 million by 2027

Prothrombin Complex Concentrates Segment has the Largest Share of Product in the Europe Anticoagulant Reversal Drug Market during 2020–2027

According to The Insight Partners market research study on “Europe Anticoagulant Reversal Drug Market to 2027 – COVID-19 Impact and Regional Analysis and Forecast by Product, and Distribution Channel,” is expected to reach US$ 655.4 million by 2027 from US$ 270.0 million in 2019. The market is estimated to grow at a CAGR of 12.4% from 2019 to 2027. The report provides trends prevailing in the Europe anticoagulant reversal drug market along with the drivers and restraints pertaining to the market growth. The rise in the prevalence of atrial fibrillation (AFiB) and an increase in prevalence of stroke are drivers growing the Europe anticoagulant reversal drug market. However, the market is expected experiencing slow growth during the forecast period owing to the high cost of anticoagulant reversal drugs.

The market for anticoagulant reversal drug market is segmented into product, and application. Based on product, the market is segmented into prothrombin complex concentrates, vitamin K, andeXXa, protamine, idarucizumab, and tranexamic acid. In 2019, the prothrombin complex concentrates accounted for the largest share and is expected to grow due to increasing demand. It is widely accepted as a reliable and fast alternative to fresh frozen plasma to control excessive bleeding as it has properties to reverse the effects of oral anticoagulant treatments. On the other hand, AndeXXa is expected to grow at the fastest CAGR during the forecast period. 

Boehringer Ingelheim International GmbH, Pfizer Inc, Octapharma AG, AMAG PHARMACEUTICALS, INC., Fresenius Kabi AG, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), CSL Limited, and Grifols, S.A. are among the leading companies in the Europe anticoagulant reversal drug market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in April 2018, Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has provided full approval for Praxbind (idarucizumab), the specific reversal agent for Pradaxa (dabigatran etexilate mesylate).

The report segments the Europe Anticoagulant Reversal Drug market as follows:

By Product

• Prothrombin Complex Concentrates
• Vitamin K
• Protamine
• Tranexamic Acid
• Idarucizumab
• AndeXXa

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Country

• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe